( tic resistant bacterial infections are...)Data on Telavancin and Micafungin Hold Promise of New Therapeutic,Options in Fight Against Serious Infectious Disease,Health

tic resistant bacterial infections are an emerging issue in hospitals and there is a real risk that we are fast running out of effective treatment options. The results of ATLAS 1 and ATLAS 2 demonstrate that telavancin may offer a new option in our fight against serious bacterial infections".

Telavancin is currently undergoing regulatory review at the U.S. Food and Drug Administration (FDA). Telavancin is a novel, rapidly bactericidal lipoglycopeptide with activity against important Gram-positive bacteria. Telavancin possesses a unique, multivalent, multifunctional mode of action that inhibits bacterial cell wall synthesis and disrupts the functional integrity of the bacterial cell membrane.

Micafungin data

Micafungin data presented show that micafungin demonstrates broad-spectrum efficacy against Candida infections.(8) More specifically data showed that in adult patients with deep, invasive Candida, micafungin was associated with efficacy comparable to established treatments, liposomal amphotericin B (L-AmB) and intravenous caspofungin,(9) and that there were significant safety advantages of micafungin over L-AmB in terms of a difference in acute infusion related reactions and Estimated Glomerular Filtration Rate (eGFR).(10) Data presented also showed that in paediatric patients with invasive candidiasis or candidaemia, micafungin was as effective as standard therapy with AmBisome(R) (L-AmB), with fewer patients experiencing treatment-related adverse events and fewer discontinuations.(11)

Micafungin is currently undergoing clinical evaluation at the EMEA. Micafungin is licensed in the US for the treatment of oesophageal candidiasis and for the prophylaxis of fungal infections caused by Candida in patients who are undergoing a haematopoietic stem cell transplant.

Commenting on the data presented at ECCMID, Dr John Bolodeoku, European Senior Medical Director, Astellas Pharma Inc. said, "Effective prevention and treatment strategies
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
2. New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
3. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
4. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
5. Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid Arthritis Study
6. Trial Results with Intranasal Fentanyl Hold Promise for Treatment of Breakthrough Pain in Cancer
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
9. RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer
10. Alzheimers Drug Shows Promise in Fighting Cancer
11. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer